The microsatellite status and tumor stage of colon tumors are important factors determining the ensuing immune response to the tumor as well as patient outcome in colon cancer [2, 27, 28], and we next wanted to investigate frequencies of CD39+ putative eTreg in the tumors in relation to clinical parameters. This evidence concerns the gene ENTPD1 and malignant colon neoplasm.